Nu Skin Enterprises (NYSE:NUS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Nu Skin’s shares have declined and underperformed the industry in the past month. The company has been struggling with declining gross margins for a while. Persistent declines in gross margin levels pose considerable threats for the company’s overall profitability. Moreover, Nu Skin remains exposed to significant currency risks resulting from international markets and stiff competition from the existence of strong peers and abundant product alternatives. Nonetheless, strong regional performance, as well as expanding sales leaders and customers bode well for the company. Notably, these upsides aided the company’s second-quarter 2018 results, marking its third consecutive period of year-on-year top- and bottom-line increases. To sustain such solid trends, Nu Skin is on track with initiatives to enhance technological capabilities, along with well-knit product launches and marketing programs.”
Other research analysts have also issued reports about the stock. DA Davidson started coverage on shares of Nu Skin Enterprises in a research note on Tuesday, October 9th. They issued a “buy” rating and a $92.00 price objective on the stock. Jefferies Financial Group reissued a “buy” rating and set a $98.00 price target on shares of Nu Skin Enterprises in a research report on Tuesday, September 4th. Finally, Stifel Nicolaus raised shares of Nu Skin Enterprises from a “sell” rating to a “hold” rating and raised their price target for the company from $57.00 to $70.00 in a research report on Thursday, August 2nd. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Nu Skin Enterprises has a consensus rating of “Buy” and a consensus price target of $86.29.
Shares of Nu Skin Enterprises stock traded down $0.03 during trading hours on Monday, reaching $68.63. The company’s stock had a trading volume of 5,225 shares, compared to its average volume of 468,632. Nu Skin Enterprises has a one year low of $59.31 and a one year high of $88.68. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of 21.32, a price-to-earnings-growth ratio of 2.35 and a beta of 1.06. The company has a current ratio of 1.82, a quick ratio of 1.19 and a debt-to-equity ratio of 0.46.
Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings data on Thursday, August 2nd. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.18. Nu Skin Enterprises had a net margin of 5.74% and a return on equity of 25.67%. The firm had revenue of $704.19 million for the quarter, compared to analyst estimates of $642.16 million. During the same period last year, the firm earned $0.77 earnings per share. The business’s quarterly revenue was up 28.0% compared to the same quarter last year. On average, research analysts forecast that Nu Skin Enterprises will post 3.61 EPS for the current year.
In related news, General Counsel D Matthew Dorny sold 2,500 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $82.18, for a total transaction of $205,450.00. Following the transaction, the general counsel now directly owns 33,871 shares of the company’s stock, valued at $2,783,518.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph Y. Chang sold 10,600 shares of the firm’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $82.13, for a total transaction of $870,578.00. Following the transaction, the insider now directly owns 63,416 shares in the company, valued at $5,208,356.08. The disclosure for this sale can be found here. Insiders have sold 42,850 shares of company stock worth $3,523,563 over the last three months. 3.00% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of NUS. BlackRock Inc. increased its holdings in Nu Skin Enterprises by 11.5% during the second quarter. BlackRock Inc. now owns 6,143,407 shares of the company’s stock worth $480,352,000 after buying an additional 635,246 shares during the last quarter. Millennium Management LLC increased its holdings in Nu Skin Enterprises by 937.5% during the first quarter. Millennium Management LLC now owns 422,098 shares of the company’s stock worth $31,113,000 after buying an additional 381,414 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Nu Skin Enterprises by 51.1% during the second quarter. Renaissance Technologies LLC now owns 814,000 shares of the company’s stock worth $63,647,000 after buying an additional 275,200 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Nu Skin Enterprises by 112.2% during the second quarter. Acadian Asset Management LLC now owns 368,804 shares of the company’s stock worth $28,834,000 after buying an additional 194,990 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its holdings in Nu Skin Enterprises by 140.2% during the second quarter. BNP Paribas Arbitrage SA now owns 217,844 shares of the company’s stock worth $17,033,000 after buying an additional 127,151 shares during the last quarter. Institutional investors and hedge funds own 76.00% of the company’s stock.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Read More: Short Selling Stocks and Day Traders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.